Uddin Mohammad A, Kubra Khadeja-Tul, Sonju Jafrin Jobayer, Akhter Mohammad S, Seetharama Jois, Barabutis Nektarios
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA.
Med Drug Discov. 2020 Jun;6. doi: 10.1016/j.medidd.2020.100046. Epub 2020 May 17.
Inhibition of Hsp90 is associated with anti-inflammatory effects. We employed human lung microvascular endothelial cells to investigate the effects of the Hsp90 inhibitors 17-AAG, AUY-922 and 17-DMAG in the unfolded protein response (UPR) and viability of lung cells. Our observations indicate that moderate doses of those compounds trigger the activation of the UPR without inducing lethal effects . Indeed, AUY-922 triggered UPR activation in the lungs of C57BL/6 mice. UPR has been previously involved in the enhancement of the lung endothelial barrier function. Thus, the present study suggests that the barrier protective effects of Hsp90 inhibition in the lung microvasculature are highly probable to be associated with the activation of the UPR. Hence, the development of novel compounds which stochastically capacitate the repairing elements of UPR, may deliver new therapeutic possibilities against the severities of the acute respiratory distress syndrome.
热休克蛋白90(Hsp90)的抑制与抗炎作用相关。我们利用人肺微血管内皮细胞来研究Hsp90抑制剂17-AAG、AUY-922和17-DMAG在未折叠蛋白反应(UPR)及肺细胞活力方面的作用。我们的观察结果表明,这些化合物的中等剂量可触发UPR的激活而不诱导致死效应。事实上,AUY-922在C57BL/6小鼠的肺中触发了UPR激活。UPR此前已参与肺内皮屏障功能的增强。因此,本研究表明,Hsp90抑制在肺微血管中的屏障保护作用极有可能与UPR的激活相关。因此,开发能够随机增强UPR修复元件的新型化合物,可能为对抗急性呼吸窘迫综合征的严重程度带来新的治疗可能性。